Impax Laboratories Inc (IPXL)

[mlkrborn]

Impax Labs Submits New Drug Application for IPX066 in Parkinson's Disease (IPXL) 19.89 : Impax Pharmaceuticals, the branded products division of IPXL announced the submission of Impax's New Drug Application for IPX066 to the U.S. Food and Drug Administration for the treatment of idiopathic Parkinson's disease. IPX066 is a patented extended release capsule formulation of carbidopa-levodopa. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) for territories outside the U.S. and Taiwan.